ArticleBMC cancer2025
The clinical value of predicting lymphovascular invasion in patients with invasive lung adenocarcinoma based on the intratumoral and peritumoral CT radiomics models.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveLung cancer remains the leading cause of cancer-related deaths worldwide, and lymphovascular invasion (LVI) is an important pathological indicator affecting the prognosis of lung cancer patients. Traditional imaging techniques face challenges in effectively and accurately predicting vascular invasion, but integrating clinical indicators with radiomics features is expected to improve the non-invasive preoperative prediction of LVI, providing valuable reference for clinical treatment decisions. This study aimed to investigate the clinical value of predicting LVI in patients with invasive lung adenocarcinoma (LUAD) based on the intratumoral and peritumoral CT radiomics models. PATIENTS AND
methodsThe 384 patients with invasive LUAD from Institution 1 were randomly divided into training (n = 268) and internal validation (n = 116) sets with a ratio of 7:3, and 251 patients from Institution 2 were used as the external validation set. Altogether, 1226 features were extracted from the tumor gross (GT), gross tumor and peritumor (GPT), and peritumor(PT), respectively. Clinical independent predictors for LVI in patients with invasive LUAD were screened using univariate and multivariate logistic regression analysis, a combined model that included clinical predictors and optimal Radscore was constructed, and a nomogram was drawn. All cases were diagnosed using histopathological examination results as the gold standard.
resultsThe GPT model showed better predictive efficacy than the GT and PT models, with the area under the curve (AUC) of 0.83, 0.79, and 0.75 in the training, internal validation, and external validation sets, respectively. In the clinical model, the preoperative carcinoembryonic antigen (CEA) level, tumor diameter, and spiculation were the independent predictors. The combined model containing the independent predictors and the GPT-Radscore significantly predicted LVI in patients with invasive LUAD, with AUCs of 0.84, 0.82, and 0.77 in the three cohorts, respectively.
conclusionThe CT scan-based radiomics model which including intratumoral and peritumoral radiomics features could effectively predict LVI in LUAD patients, and the predictive efficacy were further improved by combining clinically independent predictors. This study holded significant clinical importance, as it provided a non-invasive biomarker for the preoperative prediction of LVI status in lung cancer patients, thereby identifying subgroups with poor prognosis. It demonstrated great potential for risk stratification and guiding personalized treatment strategies in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.